SLC5A2 and type 2 diabetes mellitus: Empagliflozin is a sodium–glucose cotransporter (SGLT-2) inhibitor that was approved in August 2014 by the Food and Drug Administration (FDA) to be used as an oral antihyperglycemic agent for the treatment of type 2 diabetes mellitus (T2DM) [4], and has since gained popularity due to its cardioprotective properties [5].